MedTrace Logo

A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants

NCT05483998 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-05-20

No results posted yet for this study

Summary

This phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TLC-2716 after single- and multiple-ascending doses in healthy subjects.

Conditions

  • Healthy Subjects

Interventions

DRUG

TLC-2716

TLC-2716

OTHER

Placebo

Placebo to match

Sponsors & Collaborators

  • OrsoBio, Inc

    lead INDUSTRY

Principal Investigators

  • OrsoBio Study Director · OrsoBio, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-09
Primary Completion
2023-04-13
Completion
2023-06-18

Countries

  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05483998 on ClinicalTrials.gov